About

I am a Senior Lecturer in Biomedical Sciences. I am a Fellow of the Higher Education Academy (FHEA) and Fellow of the Institute of Biomedical Sciences (FIBMS) and HCPC registered.

Teaching responsibilities

• Haematology and Transfusion Science
• Biomedical Biotechnology

Research interests

My research interests are in the field of metabolic syndromes, particularly type 2 diabetes mellitus and obesity ('diabesity'). I have studied risk factors associated with diabesity including neurodegeneration (Alzheimer's disease). I have an interest in the development of novel peptides/nutraceuticals for the treatment and management of diabetes, its complication and Alzheimer's disease. My research work has looked at neuronal stem cell proliferation and differentiation upon external stimulation. 

Membership of professional bodies

• Fellow of Institute of Biomedical Science (IBMS)
• Member of Diabetes UK charity
• Member of the Irish Endocrine Society

Qualifications

• Post Graduate Certificate in Higher education Practice 
• Good Clinical Practice (Secondary care)
• PhD in Biomedical Sciences 
• MSc Biotechnology 
• BSc Medical Laboratory Technology 
• UK Home Office personal license (Module 1-4)
• Radioisotope user license
• Radiation Protection Supervisor

Recent conferences

• Every Breath you treat (Leeds city council) conference-Invited Speaker- Understanding the impact of air pollution across the life course to improve patient outcomes- Accredited by Royal College of Physicians [October 2022)
• Parthsarathy, Vadivel; O'Harte, Finbarr; Hogg, Chris; Flatt, Peter The synthetic analogue apelin-13 amide, improves acute glucose tolerance via activation of the APJ 308 receptor in diet-induced obese diabetic mice. [Oral presentation, Irish Endocrine Society, 40th Annual meeting, 2017, Belfast]
• Parthsarathy, V; Mclaughlin, CM; Mullan, C; Harnedy, PA; Allsopp, PJ; McSorley, EM; FitzGerald, RJ and O’Harte, FPM (2015) Boarfish (Capros aper) protein hydrolysates show potent insulinotropic and GLP-1 secretory activity in-vitro and acute glucose lowering effects in-vivo. Diabetes UK conference 2015, Glasgow, Scotland, UK
• Parthsarathy, V; Mclaughlin, CM; Mullan, C; Harnedy, PA; Allsopp, PJ; McSorley, EM; FitzGerald, RJ and O’Harte, FPM (2015) Boarfish protein hydrolysates stimulate both insulin and GLP-1 secretion from cultured cells in vitro. Nutramara Conference, Dublin, Ireland
• Parthsarathy, V and Holscher, C. (2011) Novel GLP1 analogue, Liraglutide reduces inflammation in mouse model with tissue injury, 41st Annual conference, Society for Neuroscience, Washington DC, USA and Scientific conference, Alzheimer’s Research UK, Birmingham, UK
• Parthsarathy, V and Holscher, C. (2010) Chronic administration of Liraglutide reduces plaque loadand inflammation in the brains of APP/PS1 mice, 40th Annual conference, Society for Neuroscience, San Diego, USA and Alzheimer’s Research UK, Southampton, UK
• Presented my PhD work on role of GLP-1 analogue, liraglutide, on cell proliferation and inflammation in mouse brain, in Alzheimer’s association meeting, University of Ulster, Coleraine
• Presented a talk titled ‘Successful completion of PhD’ at Alzheimer’s Research UK annual conference (PhD day), Belfast, 2013

Experience in industry

• Quality officer at Zulekha Hospital in successfully working towards Joint Commission International (JCI) accreditation and ISO 9001-2000, UAE
• Member of Hospital Infection Control Committee in Zulekha Hospital, UAE.
• Organization of Blood donation camps as intern at Christian Medical College & Hospital, Vellore, India.

International experience

1) Acting member of BBMS Employer Liaison and Advisory committee- College of Medicine, Gulf Medical University, Ajman, UAE

Recent publications

• Zummo, F.P., Krishnanda, S.I., Georgiou, M., O’Harte, F.P.M., Parthsarathy, V., Cullen, K.S., Honkanen-Scott, M., Shaw, J.A.M., Lovat, P.E., and Arden, C. (2022) Exendin-4 stimulates autophagy in pancreatic β-cells via the RAPGEF/EPAC-Ca²⁺-PPP3/calcineurin-TFEB axis, Autophagy, 18:4, 799-815, DOI: 10.1080/15548627.2021.1956123
• Parthsarathy, V. et al. (2021) “Protein hydrolysates from Boarfish (Capros aper) and Atlantic salmon (Salmo salar) skin gelatin improve metabolic control in genetically obese diabetic (OB/OB) MICE,” Journal of Food Bioactives, 16. Available at: https://doi.org/10.31665/jfb.2021.16292. 
• McLaughlin, C.M., Harnedy-Rothwell, P.A., Lafferty, R.A. et al. Macroalgal protein hydrolysates from Palmaria palmata influence the ‘incretin effect’ in vitro via DPP-4 inhibition and upregulation of insulin, GLP-1 and GIP secretion. Eur J Nutr 60, 4439–4452 (2021). https://doi.org/10.1007/s00394-021-02583-3
• O’Harte, F.P.M., Parthsarathy, V., and Flatt, P.R. (2020) Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db Molecular and Cellular Endocrinology. 504, 110695
• Parthsarathy, V., McLaughlin, C.M., Harnedy, P.A., Allsopp, Crowe, W., McSorley, E.M., O’Harte, FitzGerald, R.J., F.P.M. and (2019) Boarfish (Capros aper) protein hydrolysate has potent insulinotropic and GLP‐1 secretory activity in vitroand acute glucose lowering effects in mice. International journal of food science & technology 54 (1), 271-281
• O’Harte, F.P.M., Parthsarathy, V., Hogg, C. and Flatt, P.R. (2018) Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice. PloS one, 13(8) e0202350
• Parthsarathy, V., Hogg, C., Flatt, P.R. and O’Harte, F.P.M. (2018) Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice. Diabetes, Obesity and Metabolism, 20(2) 319–327
• Harnedy, P.A., Parthsarathy, V., McLaughlin, C.M., O’Keeffe, M.B., Allsopp, P.J., McSorley, E.M., O’Harte, F.P.M. and FitzGerald, R.J. (2018) Atlantic salmon (Salmo salar) co-product-derived protein hydrolysates: A source of antidiabetic peptides. Food Research International, 106 598–606
• Harnedy, P.A., Parthsarathy, V., McLaughlin, C.M., O’Keeffe, M.B., Allsopp, P.J., McSorley, E.M., O’Harte, F.P.M. and FitzGerald, R.J. (2018) Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in vivo antidiabetic properties. Journal of Functional Foods, 40 137–145
• O’Harte, F.P.M., Parthsarathy, V., Hogg, C. and Flatt, P.R. (2017) Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. Biochemical Pharmacology, 146 165–173
• Millar, P., Pathak, N., Parthsarathy, V., Bjourson, A.J., O’Kane, M., Pathak, V., Moffett, R.C., Flatt, P.R. and Gault, V.A. (2017) Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. The Journal of endocrinology, 234(3) 255—267
• Hasib, A., Ng, M.T., Gault, V.A., Khan, D., Parthsarathy, V., Flatt, P.R. and Irwin, N. (2017) An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice. Diabetologia, 60(3) 541–552
• Parthsarathy V, Irwin N, Hasib A, Martin C, McClean S, Bhat, B,Ng, M, Flatt, P, Gault V (2016) A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties. Biochim Biophys Acta. Doi (BBA)-General Subjects 1860 (4), 757-764
• Martin, C.M., Parthsarathy, V., Hasib, A., Ng, M.T., McClean, S., Flatt, P.R., Gault, V.A. and Irwin, N. (2016) Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin. PloS one, 11(3) e0152818
• Gault, V.A., Martin, C.M.A., Flatt, P.R., Parthsarathy, V. and Irwin, N. (2015) Xenin-25[Lys13PAL]: A novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential. Acta Diabetologica, 52(3) 461–471
• Martin, C.M.A., Parthsarathy, V., Pathak, V., Gault, V.A., Flatt, P.R. and Irwin, N. (2014) Characterisation of the biological activity of xenin-25 degradation fragment peptides. The Journal of endocrinology, 221(2) 193–200
• Parthsarathy V, Hölscher C (2013) Chronic Treatment with the GLP1 Analogue Liraglutide increases Cell Proliferation and Differentiation into Neurons in an AD Mouse PLoS ONE 8(3): e58784
• Parthsarathy V, McClean PL, Hölscher C, Taylor M, Tinker C, et al. (2013) A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease. PLoS ONE 8(1): e54769
• Parthsarathy V & Holscher C (2013) The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. European Journal of pharmacology, 700(1-3), 42-50
• McClean P, Parthsarathy V, Faivre E & Hölscher C (2011): The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer’s Journal of Neuroscience.,31 (17), 6587-6594